Article Abstract

The DESolve novolimus bioresorbable Scaffold: from bench to bedside

Authors: Alessio Mattesini, Simone Bartolini, Carlotta Sorini Dini, Serafina Valente, Guido Parodi, Miroslava Stolcova, Francesco Meucci, Carlo Di Mario

Abstract

The DESolve (Elixir Medical Corporation, Sunnyvale, California, USA) is a poly-L lactide-based polymer scaffold coated with the antiproliferative and anti-inflammatory drug novolimus. The scaffold biodegrades within one year with a complete resorption in two years and in vitro bench test have shown the ability to supply the necessary radial strength to support the vessel for the critical 3- to 4-month period after implant. The DESolve showed the unique self-correction property, which may reduce the incidence of minor malapposition after deployment. Overexpansion with DESolve is safe since a high capability resistance to fracture has been demonstrated with this scaffold. The aim of this review is to provide a comprehensive overview of the available preclinical and clinical data regarding the DESolve.